01.07.2019 • News

Valtris Expands Benzyl Derivatives

Valtris Expands Benzyl Derivatives
Valtris Expands Benzyl Derivatives

US company Valtris Specialty Chemicals is investing a “significant” sum to expand capacity for benzyl derivatives in Tessenderlo, Belgium, and Maastricht, the Netherlands. The expansions are expected to be completed by the end of the first quarter of 2020.

Valtris acquired the plants from Ineos ChloroToluenes (ICT). The Independence, Ohio-headquartered group paid €111 million for both ICT and Ineos Baleycourt.

“Following the acquisition of Ineos ChloroToluenes in August last year, we have created a global business unit that builds on our existing benzyl chloride production at Bridgeport, New Jersey.  In order to meet growing market demand for chlorotoluene derivatives, we are pleased to show further commitment to this industry and our customers by investing for long-term growth,” said Valtris CEO Paul Angus.

Louise Calviou, vice president, global advanced organics at Valtris, added that the expansions further strengthen its position as a supplier, particularly for benzyl alcohol, benzaldehyde, benzoylchloride and ortho-chlorobenzylchloride.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read